According to our research report “ Clinical Trials Market in Russia”, the Russian clinical trial market has been growing at a healthy rate for the last few years. The factors that have been fuelling the growth of the Russian clinical trial market largely include high patient recruitment rate, reasonable study costs, and good data quality. Besides, the increasing research and developments in the domestic pharma industry will drive the growth in number of clinical trials in the Russian clinical trial market. The number of clinical studies performed in Russia reached around 577 in 2009 and is expected to touch 700 by the end of 2012.
Among various therapy segments, oncology holds the highest share in total number of clinical trials conducted in the country. The rising prevalence of cancer in the country is the main reason for this dominance. This is followed by respiratory, endocrine, and metabolic diseases segments. In future as well, these therapies are expected to dominate the overall market. Most of the clinical trials in 2009 were conducted in Phase-III stage, followed by Phase-II, and Phase-IV. The same trend is likely to continue in future.
A number of domestic and international players have entered the Russian clinical trials market over the past few years, leading to diversification in the industry. However, clinical trials by local players continue to lead the market. It has been observed that sponsors from foreign countries are generally attracted by the quality standards of the Russian clinical studies. Patient recruitment is one of the most important factors while deciding the potential of clinical trial industry. The recruitment of patients depends on numerous factors discussed in our report.
We have found that the cost of conducting clinical trials in Russia is quite low in comparison to the other European and American countries. Backed by the low cost and other factors identified in our report, growth in the Russian clinical trial industry is likely to outperform the growth of clinical trial industry in other countries.
For more information visit: http://www.rncos.com/Report/IM189.htm |
